Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Achmea Investment Management B.V.

Achmea Investment Management B.V. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 250,588 shares of the biopharmaceutical company’s stock after acquiring an additional 5,244 shares during the period. Achmea Investment Management B.V.’s holdings in Gilead Sciences were worth $23,147,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC boosted its stake in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $113.99 on Thursday. The company has a market cap of $141.96 billion, a P/E ratio of 308.08, a PEG ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The business’s 50-day simple moving average is $100.99 and its 200 day simple moving average is $92.33.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.77%. Gilead Sciences’s payout ratio is currently 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 311,285 shares of company stock worth $31,284,910 in the last three months. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently commented on GILD shares. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Citigroup began coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Finally, Mizuho raised their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.